X-ray imaging was able to detect all common particulates in lyophilised drug product and provide information of the cake structure in a new study.
List view / Grid view
Imfinzi plus chemotherapy is the first immunotherapy combination to demonstrate superior clinical outcomes over standard of care for BTC.
Dupixent® reduced eosinophilic oesophagitis symptoms by 64 percent compared to placebo and met primary endpoints in second Phase III study.
The vaccine showed a relative vaccine efficacy of 95.6 percent and is the first efficacy results from a COVID-19 vaccine booster trial.
Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.
Researchers have created a new workflow using pepsin to expedite the LC-MS analysis of adeno associated virus (AAV) capsid proteins for gene therapies.
Dupixent® is the first biologic to significantly reduce itch and skin lesions in Phase III trial for prurigo nodularis.
Scientists have developed a stabiliser-free, non-toxic poly(lactic-co-glycolic acid) (PLGA) nanoparticle formulation for use in drug and vaccine delivery.
The highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7kg in Phase III study.
A Swedish study found that heterologous Vaxzevria and mRNA prime-boost vaccination is effective against COVID-19.
Host cell protein-automated iterative mass spectrometry (HCP-AIMS) enables the robust, reproducible and high throughput analysis of host cell proteins, says study.
Interferon treatment with a bone marrow transplant bolstered outcomes for patients with advanced, high-risk leukaemia.
Researchers have compiled a repository of clinical and in vitro data for excipients to enable their potential to interact with drugs to be modelled.
Here, EPR summarises a review outlining how different sample preparation protocols, culture media and conditions affect MALDI-TOF MS identification of bacteria.
Manufacturers can submit their novel excipients for FDA review under the voluntary Novel Excipient Review Pilot Program.